Ratings by Cantor Fitzgerald
| Date | Analyst | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|---|
| 3/29/2023 | Charles Duncan | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
87.00 (83.00) |
|
Details | |
| 3/28/2023 | Pete Stavropoulos | Orchard Therapeutics | ORTX | Maintain | Overweight (N/A) |
15.00 (3.00) |
|
Details | |
 |
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
| 3,547 more... | |||||||||
